WILMINGTON, Del. / Jan 24, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Guggenheim Healthcare Talks l Oncology Day on Wednesday, February 8, 2023 at 1:35 p.m. (EST) in New York.
The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
| Last Trade: | US$65.06 |
| Daily Change: | -0.98 -1.48 |
| Daily Volume: | 3,114,226 |
| Market Cap: | US$12.530B |
May 27, 2025 April 29, 2025 April 25, 2025 April 23, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
